Authors: Balhara YP
PMID: 24380101 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

CONCLUSION: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing.
PMID: 23264315 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

Updated Date: Dec 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Dec 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ImportancePrescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy.ObjectiveTo determine the efficacy of buprenorphine taper vs ongoing maintenance therapy in primary care–based treatment for prescription opioid dependence.Design, Setting, and ParticipantsWe conducted a 14-week randomized clinical trial that enrolled 113 patients with prescription opioid dependence from February 17, 2009, through February 1, 2013, in a single primary care site.InterventionsPatients were randomized to bupre…

ImportancePrescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy.ObjectiveTo determine the efficacy of buprenorphine taper vs ongoing maintenance therapy in primary care–based treatment for prescription opioid dependence.Design, Setting, and ParticipantsWe conducted a 14-week randomized clinical trial that enrolled 113 patients with prescription opioid dependence from February 17, 2009, through February 1, 2013, in a single primary care site.InterventionsPatients were randomized to bupre…

CONCLUSIONS: Treatment with higher doses of buprenorphine/naloxone was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost.
PMID: 25295655 [PubMed – in process] (Source: Postgraduate Medicine)

CONCLUSIONS: Treatment with higher doses of buprenorphine/naloxone was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost.
PMID: 25295655 [PubMed – in process] (Source: Postgraduate Medicine)

Researchers at the University of Cincinnati have begun studying whether iPads with facial recognition software can verify that patients are taking medications prescribed to combat drug abuse.

The software from New York-based AiCure is designed to confirm that a patient ingested the right medication at the right time.

The clinical study involving 140 patients focuses on Suboxone, a medication prescribed as maintenance therapy for opioid addiction, said Dr. Eugene Somoza of the Cincinnati Addiction… (Source: bizjournals.com Health Care:Biotechnology headlines)

Researchers at the University of Cincinnati have begun studying whether iPads with facial recognition software can verify that patients are taking medications prescribed to combat drug abuse.

The software from New York-based AiCure is designed to confirm that a patient ingested the right medication at the right time.

The clinical study involving 140 patients focuses on Suboxone, a medication prescribed as maintenance therapy for opioid addiction, said Dr. Eugene Somoza of the Cincinnati Addiction… (Source: bizjournals.com Health Care:Biotechnology headlines)